Volume : 11, Issue : 12, December – 2024
Title:
A REVIEW OF: SUSTAINED RELEASE TABLET OF DOXAZOSIN MESYLATE FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
Authors :
N.Madhavi *, T.Nikhitha, T.Rama Rao
Abstract :
Evidence from various studies has shown that even a very small reduction in the blood pressure explains the majority of benefits in cardiovascular outcomes. Although doxazosin is a relatively old drug, it is a very effective add-on therapeutic agent. It has been used in a variety of clinical trials, including different groups of hypertensive patients such as diabetics, the elderly, patients with benign prostatic hyperplasia or hypercholesterolaemia, the obese or Afro-Americans and in combination with all major groups of antihypertensive drugs such as: calcium channel antagonists, diuretics, beta-adrenoreceptor antagonists, angiotensin-converting enzyme inhibitors and angiotensin-2 receptor blockers. The purpose of this article is to review the role of doxazosin in the current treatment of hypertension. English-language reports published in 1986 – 2007 were retrieved. In these studies doxazosin in either standard or extended-release formulation was added as a second- or third-line agent. The two formulations of doxazosin, although chemically identical, appear to differ in some other effects. A large proportion of patients demonstrated a favorable blood pressure response with relatively few treatment-associated side effects showing that this drug appears to be a valuable add-on antihypertensive treatment option. Doxazosin reduces blood pressure and additionally influences other risk factors of coronary heart disease. However, it should be clearly stated that the clinical role of ‘beyond blood pressure’ effects of doxazosin are largely undetermined.
Key words: Doxazosin Mesylate, Sustained release tablet, High blood pressure and benign prostatic hyperplasia.
Cite This Article:
Please cite this article in press N.Madhavi et al., A Review Of: Sustained Release Tablet Of Doxazosin Mesylate For The Treatment Of Benign Prostatic Hyperplasia.,Indo Am. J. P. Sci, 2024; 11 (12).
Number of Downloads : 10
References:
1. M.m. Gupta , ray brijesh. A Review On: Sustained Release Technology. International Journal of Therapeutic Applications, Volume 8, 2012, 18 – 23.
2. Chien Y. W. Novel Drug Delivery System 1992; 2: 139 – 140.
3. Altaf AS, Friend DR, MASRx and COSRx Sustained-Release Technology in Rathbone MJ, Hadgraft J, Robert MS, Modified Release Drug Delivery Technology, Marcell Dekker Inc., New York, 2003.
4. Gwen MJ and Joseph RR, In Banker GS and Rhodes CT, Eds., Modern Pharmaceutics, 3rd Edn , Vol. 72, Marcel Dekker Inc. New York, 1996, 575.
5. Salsa T, Veiga F And Pina M.E, Drug Develop. Ind. Pharm., 1997, 23, 931.
6. Jantez GM, Robinson JR. Sustained andcontrolled release drug delivery systems. In: Banker GS, Rhodes CT, editors. Modern pharmaceutics. 3rd edition. New York: marcel dekker inc; 1996.
7. Popli H, shrma SN. Trends in oral sustained release formulations-I The eastern pharmacist 1989; 32: p. 99-103.
8. Remington. The Science and Practice of pharmacy, 20th Edition, vol. I: 903-913.
9. Abhijeet Welankiwar. Review: Sustained Release Dosage Forms.
10. Piyush Mandhar , Gayitri Joshi. Development of Sustained Release Drug Delivery System: A Review. Asian Pac. J. Health Sci., 2015; 2(1): 179-185 . 11. Bechgaard H, Nielson GH. Controlled release multiple units and single unit dosage. Drug Dev & Ind Pharm 1978; 4(1): 53-67.
11. Qiu Y, Zhang G, Wise DL. Handbook of pharmaceutical controlled release technology. New York: Marcell Dekke, 3rd edition 2000.
12. Chugh I, Seth N, Rana AC, Gupta S. Oral sustained release drug delivery system: anoverview. International research journal of pharmacy 2012; 3(5): 57-62.
13. Chauhan MJ, Patel SA. A Concise Review on Sustained Drug Delivery System and Its
14. Opportunities. Am. J. PharmTech Res 2012; 2(2): 227-238.
15. Remington. The Science and Practice of pharmacy. Lippincott Williams & Wilkins, 20th Edition 2006.
16. Davis SS, Hardy JG, Taylor MJ, Whalley DR, Wilson CG. Comparative study of gastrointestinal.
17. Rakesh Roshan Mali, Vaishali Goel, Sparsh Gupta. Novel Study in Sustained Release Drug Delivery System: A Review. Int. J. Pharm. Med. Res. 2015; 3(2):204-215.
18. Patel Chirag J., Satyanand T., Novel Sustained Release Drug Delivery: A Modern Review, International Journal of Applied Pharmaceutics 2014;1:115-119.
19. Pogula M., Nazeer S., Extended Release Formulation, International Journal of Pharmacy & Technology 2010;2:625- 684.
20. Parashar T., Soniya S., Singh V., Novel oral sustained release technology: A Concise Review, International Journal of Research and Development in Pharmacy andLife Sciences 2013;262-269.
21. Patel Kundan K., Patel Mehul S., Bhatt Nayana M., An Overview: Extended Release Matrix Technology, International Journal of Pharmaceutical and Chemical Sciences 2012;112-115.
22. Rao Raghavendra NG., Raj Prasanna Richard K., Nayak S., Review on Matrix Tablet as Sustained Release,International Journal of Pharmaceutical Research & Allied Sciences 2013;2:1700-1717.
23. Wadher G., Satish B., Tukaram MK., Recent (Aspects) trend on Sustained drug delivery system, International Journal of Chemical and Pharmaceutical Sciences 2013;4:1-7.
24. Kumar Sampath KP., Bhowmik D., Srivastava S., Sustained release drug delivery system potentials, International Journal of Pharmaceutics 2010;2:751-754.
25. Cockett AT, Aso Y, Denis L, et al. World Healh Organization Consensus Committee recommendations concerning the diagnosis of BPH. Prog Urol. 1991;1:957–972.
26. Vela R, Martín JM, Calahorra J, et al. Validación culturaly linguistica en castellano del baremo internacional de sín‐tomas prostáticos (I‐PSS). Ac Urol Espa. 1994;18:841–847.
27. https://pubchem.ncbi.nlm.nih.gov/compound/Doxazosin-Mesylate
28. https://en.wikipedia.org/wiki/Doxazosin
29. https://go.drugbank.com/drugs/DB00590
30. https://www.drugs.com/doxazosin.html